Skip to main content
SpringerLink
Log in

Second look at trial data confirms niacin's link with unexpected AEs

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. see Reactions 1443 p3; 801161309

  2. see Reactions 1354 p4; 803055060

Reference

  • Oxford University Clinical Trial Service Unit. Adverse Effects in AIM-HIGH trial of Niaspan are Consistent With the Results Reported From HPS2-THRIVE Trial of ER Niacin Plus Laropiprant. Media Release : 25 Mar 2013. Available from: URL: http://www.ctsu.ox.ac.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Second look at trial data confirms niacin's link with unexpected AEs. Reactions Weekly 1447, 3 (2013). https://doi.org/10.1007/s40278-013-2366-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-013-2366-9

Search

Navigation